Abstract

This observational study explored the association between proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) use and the risk of chronic kidney disease (CKD). Using the National Health Insurance Service-National Sample Cohort (NHIS-NSC) and six-hospital electronic health record (EHR) databases, CKD incidence was analyzed among PPI and H2RA users. Propensity score matching was used to balance baseline characteristics, with 1,869 subjects each in the PPI and H2RA groups from the NHIS-NSC, and 5,967 in EHR databases. CKD incidence was similar for both groups (5.72/1000 person-years vs. 7.57/1000 person-years; HR = 0.68; 95% CI, 0.35–1.30). A meta-analysis of the EHR databases showed no significant increased CKD risk associated with PPI use (HR = 1.03, 95% CI: 0.87–1.23). These results suggest PPI use may not increase CKD risk compared to H2RA use, but the potential role of PPI-induced CKD needs further research. Clinicians should consider this when prescribing long-term PPI therapy.

Details

Title
Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists
Author
Kweon, Takhyeon 1 ; Kim, Yerim 1 ; Lee, Kyung Joo 1 ; Seo, Won-Woo 1 ; Seo, Seung In 1 ; Shin, Woon Geon 1 ; Shin, Dong Ho 1 

 Kangdong Sacred Heart Hospital, Hallym University, Department of Internal Medicine, College of Medicine, Seoul, Korea (GRID:grid.488451.4) (ISNI:0000 0004 0570 3602) 
Pages
21169
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2895587637
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.